This morning we watched Illumina drop -1.9% to a price of $139.77 per share. The large-cap Medical Specialities company is now trading -34.63% below its average target price of $213.82. Analysts have set target prices ranging from $125.0 to $318.0 per share for Illumina, and have given the stock an average rating of hold.
Illumina's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 4.0%. The stock's short ratio is 4.38. The company's insiders own 0.27% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 93.5%. In conclusion, we believe there is mixed market sentiment regarding Illumina.
Institutions Invested in Illumina
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-06-30 | Vanguard Group Inc | 10% | 15,630,823 | $2,184,720,197 |
| 2023-06-30 | Baillie Gifford and Company | 9% | 13,973,317 | $1,953,050,576 |
| 2023-06-30 | Blackrock Inc. | 9% | 13,464,324 | $1,881,908,623 |
| 2023-06-30 | Morgan Stanley | 5% | 7,544,967 | $1,054,560,069 |
| 2023-06-30 | State Street Corporation | 4% | 6,715,664 | $938,648,385 |
| 2023-06-30 | Edgewood Management Llc | 4% | 5,572,973 | $778,934,460 |
| 2023-06-30 | Wellington Management Group, LLP | 3% | 5,275,549 | $737,363,506 |
| 2023-06-30 | Polen Capital Management, LLC | 3% | 5,097,461 | $712,472,145 |
| 2023-06-30 | Janus Henderson Group PLC | 3% | 4,783,774 | $668,628,112 |
| 2023-06-30 | Loomis Sayles & Company, LP | 2% | 3,799,690 | $531,082,687 |
